Compare CCS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | NBTX |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2014 | 2018 |
| Metric | CCS | NBTX |
|---|---|---|
| Price | $65.58 | $41.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $64.80 | $36.00 |
| AVG Volume (30 Days) | ★ 329.5K | 80.4K |
| Earning Date | 04-22-2026 | 03-31-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $4,117,816,000.00 | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | $10.84 | N/A |
| P/E Ratio | $78.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.28 | $4.93 |
| 52 Week High | $76.00 | $57.14 |
| Indicator | CCS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 55.76 |
| Support Level | $56.22 | $38.89 |
| Resistance Level | $66.11 | $42.40 |
| Average True Range (ATR) | 2.19 | 2.11 |
| MACD | -0.78 | 0.46 |
| Stochastic Oscillator | 22.80 | 74.18 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.